These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder. Aldosary F; Norris S; Tremblay P; James JS; Ritchie JC; Blier P Int J Neuropsychopharmacol; 2022 Apr; 25(4):283-292. PubMed ID: 34958348 [TBL] [Abstract][Full Text] [Related]
3. Further studies on conformationally constrained tricyclic tropane analogues and their uptake inhibition at monoamine transporter sites: synthesis of (Z)-9-(substituted arylmethylene)-7-azatricyclo[4.3.1.0(3,7)]decanes as a novel class of serotonin transporter inhibitors. Zhang A; Zhou G; Hoepping A; Mukhopadhyaya J; Johnson KM; Zhang M; Kozikowski AP J Med Chem; 2002 Apr; 45(9):1930-41. PubMed ID: 11960503 [TBL] [Abstract][Full Text] [Related]
4. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. Benmansour S; Cecchi M; Morilak DA; Gerhardt GA; Javors MA; Gould GG; Frazer A J Neurosci; 1999 Dec; 19(23):10494-501. PubMed ID: 10575045 [TBL] [Abstract][Full Text] [Related]
5. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Béïque JC; Lavoie N; de Montigny C; Debonnel G Eur J Pharmacol; 1998 May; 349(1):129-32. PubMed ID: 9669506 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Gilmor ML; Owens MJ; Nemeroff CB Am J Psychiatry; 2002 Oct; 159(10):1702-10. PubMed ID: 12359676 [TBL] [Abstract][Full Text] [Related]
7. Regulatory effects of reboxetine treatment alone, or following paroxetine treatment, on brain noradrenergic and serotonergic systems. Gould GG; Pardon MC; Morilak DA; Frazer A Neuropsychopharmacology; 2003 Sep; 28(9):1633-41. PubMed ID: 12825093 [TBL] [Abstract][Full Text] [Related]
8. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Sánchez C; Bergqvist PB; Brennum LT; Gupta S; Hogg S; Larsen A; Wiborg O Psychopharmacology (Berl); 2003 Jun; 167(4):353-62. PubMed ID: 12719960 [TBL] [Abstract][Full Text] [Related]
9. Biaryl analogues of conformationally constrained tricyclic tropanes as potent and selective norepinephrine reuptake inhibitors: synthesis and evaluation of their uptake inhibition at monoamine transporter sites. Zhou J; Zhang A; Kläss T; Johnson KM; Wang CZ; Ye YP; Kozikowski AP J Med Chem; 2003 May; 46(10):1997-2007. PubMed ID: 12723962 [TBL] [Abstract][Full Text] [Related]
10. Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters. Orjales A; Mosquera R; Toledo A; Pumar MC; García N; Cortizo L; Labeaga L; Innerárity A J Med Chem; 2003 Dec; 46(25):5512-32. PubMed ID: 14640559 [TBL] [Abstract][Full Text] [Related]
13. Chronoamperometry to determine differential reductions in uptake in brain synaptosomes from serotonin transporter knockout mice. Perez XA; Andrews AM Anal Chem; 2005 Feb; 77(3):818-26. PubMed ID: 15679349 [TBL] [Abstract][Full Text] [Related]
14. S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. Millan MJ; Gobert A; Lejeune F; Newman-Tancredi A; Rivet JM; Auclair A; Peglion JL J Pharmacol Exp Ther; 2001 Aug; 298(2):565-80. PubMed ID: 11454918 [TBL] [Abstract][Full Text] [Related]
15. Novel conformationally constrained tropane analogues by 6-endo-trig radical cyclization and stille coupling - switch of activity toward the serotonin and/or norepinephrine transporter. Hoepping A; Johnson KM; George C; Flippen-Anderson J; Kozikowski AP J Med Chem; 2000 May; 43(10):2064-71. PubMed ID: 10821718 [TBL] [Abstract][Full Text] [Related]
16. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Owens MJ; Krulewicz S; Simon JS; Sheehan DV; Thase ME; Carpenter DJ; Plott SJ; Nemeroff CB Neuropsychopharmacology; 2008 Dec; 33(13):3201-12. PubMed ID: 18418363 [TBL] [Abstract][Full Text] [Related]
17. Thiophene derivatives: a new series of potent norepinephrine and serotonin reuptake inhibitors. Zhang A; Zhou G; Rong SB; Johnson KM; Zhang M; Kozikowski AP Bioorg Med Chem Lett; 2002 Apr; 12(7):993-5. PubMed ID: 11909701 [TBL] [Abstract][Full Text] [Related]
18. In vivo effect of antidepressants on [3H]paroxetine binding to serotonin transporters in rat brain. Nadgir SM; Malviya M Neurochem Res; 2008 Nov; 33(11):2250-6. PubMed ID: 18437564 [TBL] [Abstract][Full Text] [Related]
19. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Owens MJ; Knight DL; Nemeroff CB Biol Psychiatry; 2001 Sep; 50(5):345-50. PubMed ID: 11543737 [TBL] [Abstract][Full Text] [Related]
20. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. Owens MJ; Morgan WN; Plott SJ; Nemeroff CB J Pharmacol Exp Ther; 1997 Dec; 283(3):1305-22. PubMed ID: 9400006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]